Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 8 Carcinoma, Non-Small-Cell Lung 6 Pancreatic Neoplasms 5 Ovarian Neoplasms 5 Colorectal Neoplasms 5 Neoplasm Metastasis 4 Fallopian Tube Neoplasms 4 Breast Neoplasms 4 Multiple Myeloma 3 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Rectal Neoplasms 2 Primary Myelofibrosis 2 Neoplasms 2 Myelodysplastic Syndromes 2 Mycosis Fungoides 2 Melanoma 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, T-Cell 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Large-Cell, Anaplastic 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Myeloid, Acute 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Glioblastoma 2 Colonic Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Transitional Cell 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1

Interventions

Rituximab 57 Cyclophosphamide 56 fludarabine 37 fludarabine phosphate 31 Filgrastim 27 Etoposide 22 Bortezomib 20 Melphalan 19 Gemcitabine 19 Cytarabine 17 Bendamustine Hydrochloride 17 Peripheral Blood Stem Cell Transplantation 16 Vincristine 15 pembrolizumab 14 aldesleukin 13 Prednisone 13 Doxorubicin 12 Dexamethasone 12 Busulfan 12 Whole-Body Irradiation 11 Vorinostat 11 Tacrolimus 11 Sirolimus 11 sargramostim 10 obinutuzumab 10 Lenalidomide 10 romidepsin 9 Radiotherapy 9 Rifampin 8 Paclitaxel 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Lymphoma × Immunoglobulin G × Clear all

NCT06475235 2026-02-20

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Dana-Farber Cancer Institute

Phase 1 Recruiting

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡